| Literature DB >> 35048392 |
Zhong-Hua Wang1, Bing-Qi Fu2,3, Ying-Wen Lin2,3, Xue-Biao Wei1, Heng Geng4, Wei-Xin Guo1, Hui-Qing Yuan5, You-Wan Liao1, Tie-He Qin1, Fei Li6, Shou-Hong Wang1.
Abstract
Red blood cell distribution width (RDW) was frequently assessed in COVID-19 infection and reported to be associated with adverse outcomes. However, there was no consensus regarding the optimal cutoff value for RDW. Records of 98 patients with COVID-19 from the First People's Hospital of Jingzhou were reviewed. They were divided into two groups according to the cutoff value for RDW on admission by receiver operator characteristic curve analysis: ≤11.5% (n = 50) and >11.5% (n = 48). The association of RDW with the severity and outcomes of COVID-19 was analyzed. The receiver operating characteristic curve indicated that the RDW was a good discrimination factor for identifying COVID-19 severity (area under the curve = 0.728, 95% CI: 0.626-0.830, p < 0.001). Patients with RDW > 11.5% more frequently suffered from critical COVID-19 than those with RDW ≤ 11.5% (62.5% vs. 26.0%, p < 0.001). Multivariate logistic regression analysis showed RDW to be an independent predictor for critical illness due to COVID-19 (OR = 2.40, 95% CI: 1.27-4.55, p = 0.007). A similar result was obtained when we included RDW > 11.5% into another model instead of RDW as a continuous variable (OR = 5.41, 95% CI: 1.53-19.10, p = 0.009). RDW, as an inexpensive and routinely measured parameter, showed promise as a predictor for critical illness in patients with COVID-19 infection. RDW > 11.5% could be the optimal cutoff to discriminate critical COVID-19 infection.Entities:
Keywords: COVID-19; infection; red blood cell distribution width; respiratory tract
Mesh:
Year: 2022 PMID: 35048392 PMCID: PMC9015531 DOI: 10.1002/jmv.27602
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 20.693
Figure 1The receiver operating characteristic curves (ROC) for red blood cell distribution width (RDW) in predicting the severity of COVID‐19
Baseline clinical characteristics of included patients stratified by RDW
| RDW > 11.5% ( | RDW ≤ 11.5% ( |
| |
|---|---|---|---|
| Age, years | 58.1 ± 14.8 | 54.4 ± 18.8 | 0.289 |
| Gender, female, | 23 (47.9) | 27 (54.0) | 0.547 |
| Concomitant disorders, | |||
| Hypertension | 13 (27.1) | 14 (28.0) | 0.919 |
| Diabetes | 2 (4.2) | 2 (4.0) | 1.000 |
| SBP, mmHg | 134.0 ± 24.2 | 133.4 ± 22.9 | 0.902 |
| DBP, mmHg | 82.3 ± 15.6 | 78.2 ± 12.3 | 0.155 |
| Heart rate, bpm | 89.6 ± 14.7 | 89.5 ± 17.8 | 0.980 |
| CRP, mg/L | 10.1 (1.5, 24.1) | 16.4 (4.6, 49.3) | 0.059 |
| Serum creatinine, μmol/L | 63.0 (51.9, 76.2) | 65.5 (52.8, 83.7) | 0.293 |
| eGFR, ml/min/1.73 m2 | 110.2 ± 44.1 | 120.8 ± 39.3 | 0.224 |
| ALT, U/L | 16.0 (10.0, 27.0) | 23.0 (13.0, 43.0) | 0.053 |
| WBC, ×10⁹/L | 6.7 ± 4.5 | 6.0 ± 3.8 | 0.415 |
| Hemoglobin, g/L | 116.9 ± 21.0 | 121.6 ± 15.6 | 0.207 |
| Anemia, | 22 (45.8) | 15 (30.0) | 0.106 |
| Platelet count, ×10⁹/L | 174.7 ± 75.5 | 162.4 ± 73.6 | 0.415 |
| Creatine kinase, U/L | 70.5 (51.0, 98.5) | 55.5 (36.0, 106.0) | 0.183 |
| Creatine kinase‐MB, U/L | 12.0 (10.0, 17.0) | 11.0 (9.0, 15.5) | 0.456 |
|
| 0.8 (0.3, 2.2) | 0.5 (0.2, 0.9) | 0.039 |
| Critical cases, | 30 (62.5) | 13 (26.0) | <0.001 |
| Treatment | |||
| Antibiotic therapy | 37 (77.1) | 46 (92.0) | 0.040 |
| Glucocorticoid therapy | 27 (56.3) | 21 (42.0) | 0.158 |
| Interferon therapy | 22 (45.8) | 14 (28.0) | 0.067 |
| Hospital stay, days | 25 (20, 29) | 25.0 (19.0, 32.8) | 0.536 |
| In‐hospital death | 4 (8.3) | 2 (4.0) | 0.636 |
Abbreviations: ALT, alanine transaminase; CRP, C‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RDW, red cell distribution width; SBP, systolic blood pressure; WBC, white blood cell.
Multivariate logistic regression analysis for the severity of COVID‐19
| Clinical variables | OR | 95% CI |
|
|---|---|---|---|
| Model 1 | |||
| RDW | 2.40 | 1.27, 4.55 | 0.007 |
| Age | 1.09 | 1.03, 1.16 | 0.003 |
| CRP | 1.00 | 0.98, 1.02 | 0.873 |
| eGFR<90 ml/min/1.73 m2 | 1.37 | 0.26, 7.16 | 0.711 |
| ALT | 1.02 | 1.00, 1.04 | 0.066 |
| WBC | 1.02 | 0.82, 1.26 | 0.880 |
| Anemia | 0.67 | 0.17, 2.69 | 0.575 |
|
| 1.28 | 0.98, 1.68 | 0.067 |
| Model 2 | |||
| RDW > 11.5% | 5.41 | 1.53, 19.10 | 0.009 |
| Age | 1.08 | 1.02, 1.14 | 0.010 |
| CRP | 1.00 | 0.98, 1.01 | 0.659 |
| eGFR<90 ml/min/1.73 m2 | 2.12 | 0.42, 10.81 | 0.365 |
| ALT | 1.02 | 1.00, 1.04 | 0.105 |
| WBC | 1.04 | 0.84, 1.30 | 0.701 |
| Anemia | 0.80 | 0.20, 3.22 | 0.750 |
|
| 1.31 | 1.01, 1.71 | 0.041 |
Abbreviations: ALT, alanine transaminase; CI, confidence interval; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; OR, odds ratio; RDW, red cell distribution width;WBC, white blood cell.